Audit of Antipsychotic Polypharmacy in Christchurch

1. Taylor D Paton C Kerwin R . The Maudsley Prescribing Guidelines9th edn. Informa Healthcare, London 2007.

2. National Institute of Clinical Excellence. Guidance on the Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Health Technology Appraisal No 43. Available from URL: www.nice.org.uk , 2002.

3. Tranulis C Skalli L Lalonde P Nicole L Stip E . Benefits and risks of antipsychotic polypharmacy. An evidence based review of the literature. Drug Safety 2008; 31: 7–20.

4. Waddington J Youseff H Kinsella A . Mortality in schizophrenia. antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. British Journal of Psychiatry 1998; 173: 325–329.

5. Connolly A Taylor D . Ethnicity and quality of antipsychotic prescribing among in-patients in south London. British Journal of Psychiatry 2008; 193: 161–162.

6. Kuno E Rothbard AB . Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry 2002; 159: 567–572.